Nutex Health (NASDAQ:NUTX) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Nutex Health (NASDAQ:NUTX) from a strong-buy rating to a hold rating in a research note released on Saturday.

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Nutex Health in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Nutex Health presently has an average rating of “Moderate Buy” and a consensus target price of $252.50.

Nutex Health Trading Down 14.3%

Shares of NUTX opened at $90.28 on Friday. The business’s 50-day moving average price is $136.67 and its 200 day moving average price is $124.71. The company has a current ratio of 3.20, a quick ratio of 3.18 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $638.28 million, a P/E ratio of 10.05 and a beta of 0.03. Nutex Health has a 1-year low of $40.67 and a 1-year high of $193.07.

Nutex Health (NASDAQ:NUTX) last posted its quarterly earnings results on Thursday, March 5th. The company reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.56 by ($3.95). Nutex Health had a return on equity of 18.70% and a net margin of 7.34%.The company had revenue of $151.68 million during the quarter, compared to analysts’ expectations of $258.82 million.

Institutional Trading of Nutex Health

Several institutional investors have recently bought and sold shares of the stock. Islay Capital Management LLC acquired a new position in Nutex Health during the fourth quarter worth $34,000. State of Alaska Department of Revenue acquired a new stake in shares of Nutex Health in the 3rd quarter valued at $30,000. BNP Paribas Financial Markets grew its holdings in shares of Nutex Health by 966.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock worth $40,000 after purchasing an additional 290 shares during the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of Nutex Health in the 2nd quarter worth about $44,000. Finally, Royal Bank of Canada lifted its holdings in Nutex Health by 752.4% during the 4th quarter. Royal Bank of Canada now owns 358 shares of the company’s stock valued at $59,000 after purchasing an additional 316 shares during the last quarter. Institutional investors and hedge funds own 5.32% of the company’s stock.

Nutex Health News Summary

Here are the key news stories impacting Nutex Health this week:

• Positive Sentiment: Nutex reported strong full?year 2025 results (revenue +82% y/y to $875.3M; net income and EPS up; adjusted EBITDA +152.6%) and announced a second stock repurchase program — news that can support the stock over time by reducing share count and signaling management confidence. NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM
• Positive Sentiment: Analyst/coverage pieces are discussing valuation upside given earnings growth and the buyback, which may attract long?term investors focused on fundamentals. Assessing Nutex Health (NUTX) Valuation After Earnings Growth And New Share Buyback Program
• Neutral Sentiment: Corporate press releases and financial filings provide the detailed numbers and management commentary — useful for investors doing due diligence but unlikely to move the market on their own. Company Press Release / Financial Report
• Negative Sentiment: Nutex’s most recent quarterly report missed expectations sharply (EPS $1.61 vs. $5.56 est.; revenue $151.7M vs. $258.8M), a short?term catalyst for selling as it signals volatility in recent revenue drivers. MarketBeat: Earnings Summary
• Negative Sentiment: Multiple law firms (Block & Leviton, Kuehn Law and others) have launched investigations or encouraged shareholders to contact them over potential securities fraud and fiduciary?duty claims tied to disclosure of revenue recognition and internal controls — a major overhang that raises litigation risk, potential settlements, and reputational damage. Block & Leviton Investigation Notice
• Negative Sentiment: Additional press items detail similar shareholder litigation allegations about HaloMD-related revenue recognition, internal control weaknesses, and stock?based compensation treatment — issues that could lead to restatements or future liabilities. Kuehn Law Notice
• Negative Sentiment: Local/regional reporting highlights investor outreach from law firms, amplifying negative headlines and short?term selling pressure. GazetteXtra: Investor Advisory

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight?loss services and behavioral health support. By combining in?person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost?effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail?anchored centers, offering treatment for non?life?threatening injuries and illnesses, preventive screenings and basic primary care.